Banque Cantonale Vaudoise’s Karyopharm Therapeutics KPTI Stock Holding History

Banque Cantonale Vaudoise’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,667	Closed	-$22K	–	898
2024 Q2	$22K	Hold	1,667	–	–	﹤0.01%	874
2024 Q1	$38K	Hold	1,667	–	–	﹤0.01%	819
2023 Q4	$22K	Buy	1,667 +667	+67%	+$8.99K	﹤0.01%	889
2023 Q3	$20K	Hold	1,000	–	–	﹤0.01%	1067
2023 Q2	$27K	Hold	1,000	–	–	﹤0.01%	1044
2023 Q1	$58K	Buy	1,000 +667	+200%	+$32.9K	﹤0.01%	933
2022 Q4	$17K	Hold	333	–	–	﹤0.01%	1077
2022 Q3	$27K	Hold	333	–	–	﹤0.01%	1065
2022 Q2	$23K	Hold	333	–	–	﹤0.01%	1111
2022 Q1	$37K	Buy	+333	New	+$41.5K	﹤0.01%	1082
2021 Q4	–	Sell	-3,333	Closed	-$332K	–	1364
2021 Q3	$291K	Buy	+3,333	New	+$346K	0.01%	713
2021 Q1	–	Sell	-1,333	Closed	-$310K	–	1167
2020 Q4	$310K	Hold	1,333	–	–	0.02%	630
2020 Q3	$292K	Buy	+1,333	New	+$326K	0.02%	583

Other funds holding KPTI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Banque Cantonale Vaudoise's KPTI Position: Q3 2024 in Review

Banque Cantonale Vaudoise sold out of Karyopharm Therapeutics (KPTI) in Q3 2024, closing a stake of 1,667 shares — an estimated $22K sold.

Banque Cantonale Vaudoise first reported a position in KPTI in Q3 2020 and held it in 13 quarters. The position peaked at $310K in Q4 2020. 91 funds tracked by Wall St. Rank hold KPTI as of Q3 2024.

Banque Cantonale Vaudoise reported no remaining Karyopharm Therapeutics position as of Q3 2024 after selling out during the quarter.
Banque Cantonale Vaudoise sold 1,667 Karyopharm Therapeutics shares in Q3 2024, an estimated $22K.
Banque Cantonale Vaudoise first reported a position in Karyopharm Therapeutics in Q3 2020 and held it in 13 quarters.
Banque Cantonale Vaudoise's Karyopharm Therapeutics position peaked at $310K in Q4 2020.
91 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2024.

Based on Banque Cantonale Vaudoise's 13F filing for Q3 2024, filed 8 Nov 2024.